| Myocardial Infarction
Praluent vs Brilinta
Side-by-side clinical, coverage, and cost comparison for myocardial infarction.Deep comparison between: Praluent vs Brilinta with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsBrilinta has a higher rate of injection site reactions vs Praluent based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Brilinta but not Praluent, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Praluent
Brilinta
At A Glance
SC injection
Every 2-4 weeks
PCSK9 inhibitor
Oral
Twice daily
P2Y12 platelet inhibitor
Indications
- Myocardial Infarction
- Coronary heart disease
- Cerebrovascular accident
- Angina, Unstable
- Hypercholesterolemia
- Familial hypercholesterolemia - heterozygous
- Homozygous Familial Hypercholesterolemia
- Acute Coronary Syndrome
- Myocardial Infarction
- Coronary Artery Disease
- Acute Ischemic Stroke
- Transient Ischemic Attack
- Stent thrombosis
Dosing
Hypercholesterolemia, Myocardial Infarction, Coronary heart disease, Cerebrovascular accident, Angina, Unstable 75 mg SC once every 2 weeks or 300 mg SC once every 4 weeks; may adjust to 150 mg SC every 2 weeks if LDL-C response is inadequate.
Familial hypercholesterolemia - heterozygous (adults on LDL apheresis), Homozygous Familial Hypercholesterolemia 150 mg SC once every 2 weeks; may be administered without regard to timing of LDL apheresis.
Familial hypercholesterolemia - heterozygous (pediatric, <50 kg) 150 mg SC once every 4 weeks; may adjust to 75 mg SC once every 2 weeks if LDL-C response is inadequate.
Familial hypercholesterolemia - heterozygous (pediatric, >=50 kg) 300 mg SC once every 4 weeks; may adjust to 150 mg SC once every 2 weeks if LDL-C response is inadequate.
Acute Coronary Syndrome, Myocardial Infarction, Stent thrombosis 180 mg oral loading dose, then 90 mg twice daily for the first year; after one year, 60 mg twice daily; use with aspirin 75-100 mg daily.
Coronary Artery Disease 60 mg twice daily; use with aspirin 75-100 mg daily.
Acute Ischemic Stroke, Transient Ischemic Attack 180 mg loading dose, then 90 mg twice daily for up to 30 days; use with aspirin 300-325 mg loading dose and 75-100 mg daily maintenance.
Contraindications
- Previous serious hypersensitivity reaction to alirocumab or any excipient in PRALUENT
- History of intracranial hemorrhage
- Active pathological bleeding (e.g., peptic ulcer or intracranial hemorrhage)
- Hypersensitivity (e.g., angioedema) to ticagrelor or any component of the product
Adverse Reactions
Most common (>=2%) Injection site reactions, influenza, diarrhea, myalgia, muscle spasms, contusion
Serious Hypersensitivity vasculitis, nummular eczema, angioedema
Postmarketing Angioedema, influenza-like illness
Most common (>=4%) Dyspnea, dizziness, nausea, bleeding
Serious Major bleeding, fatal/life-threatening bleeding, intracranial hemorrhage, bradycardia, ventricular pauses
Postmarketing Thrombotic Thrombocytopenic Purpura, hypersensitivity reactions including angioedema, central sleep apnea, Cheyne-Stokes respiration, rash
Pharmacology
Alirocumab is a human monoclonal antibody that inhibits PCSK9, a protein that promotes LDL receptor degradation on hepatocytes, thereby increasing LDL receptor availability and lowering circulating LDL-C levels.
P2Y12 platelet inhibitor; ticagrelor and its major metabolite reversibly interact with the platelet P2Y12 ADP-receptor to prevent signal transduction and platelet activation, with ticagrelor and its active metabolite being approximately equipotent.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Praluent
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (9/12)
Brilinta
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (3/12) · Qty limit (9/12)
UnitedHealthcare
Praluent
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (1/8) · Qty limit (1/8)
Brilinta
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (3/8)
Humana
Praluent
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Brilinta
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$50/momo
MyPraluent Copay CardCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Brilinta.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
PraluentView full Praluent profile
BrilintaView full Brilinta profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.